Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) was featured on the latest episode of The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz discussed the company's lead drug candidate, Lucid-MS, and its commercial alcohol metabolism product, unbuzzd(TM). Durkacz emphasized that Lucid-MS is being developed to address mobility loss associated with multiple sclerosis (MS) by targeting nerve damage, an area he believes remains unmet by currently available treatments.
The company is preparing for a Phase 2 clinical trial for Lucid-MS, which will be the first study to evaluate the drug candidate in MS patients following Phase 1 testing in healthy volunteers. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of MS, in preclinical models. According to the press release, the therapy aims to fill a significant gap in MS treatment, as existing therapies primarily focus on inflammation rather than nerve repair.
Durkacz also highlighted unbuzzd(TM), a product designed to accelerate blood alcohol metabolism, which is currently available in the U.S. market. Quantum BioPharma invented unbuzzd and spun out its over-the-counter version to Unbuzzd Wellness Inc., a company led by industry veterans. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and receives royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company retains full rights to develop similar products for pharmaceutical and medical uses.
The podcast appearance underscores Quantum BioPharma's dual strategy: advancing a novel therapeutic for a debilitating neurological disease while generating near-term revenue from a consumer health product. The Phase 2 trial for Lucid-MS represents a critical milestone, as positive results could validate its mechanism and open the door to a potential disease-modifying therapy for MS. Meanwhile, unbuzzd provides a steady income stream through royalties and equity, which could support further research and development.
For more details, the full press release is available at https://ibn.fm/HURxt. The latest news and updates relating to QNTM can be found at https://ibn.fm/QNTM.
